Hikma Pharmaceuticals PLC
HKMPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.62B
Close$
$44.13
91.9% upside
Current Fair Value
91.9% upsideUndervalued by 91.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.62 Billion |
|---|---|
| Enterprise Value | $6.31 Billion |
| Annual dividend | $0.86 |
| Dividend yield | 3.78% |
| Earnings per Share | $1.86 |
| Beta | 0.65 |
| Outstanding Shares | 211,747,090 |
Return
| Return on Equity | 29.96% |
|---|---|
| Return on Assets | 12.97% |
| Return on Invested Capital | 28.02% |
Valuation & Multiples
| P/E Ratio | 12.52 |
|---|---|
| PEG | -198.14 |
| Price to Sales | 0.74 |
| Price to Book Ratio | 2.09 |
| Enterprise Value to Revenue | 0.95 |
| Enterprise Value to EBIT | 5.07 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | 0.78 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$1.10
Consensus analyst estimateRevenue Estimate
$1.70 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
$1.13
Consensus analyst estimateRevenue Estimate
$1.75 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Hikma Pharmaceuticals PLC
9,500 employees
CEO: Said Samih Taleb Darwazah
Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in var...